Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-25-239173·SR ONE CAPITAL MANAGEMENT, LLC
Schedule 13D ownership disclosure
Zenas Biopharma Inc
Common Stock, $0.0001 par value · CUSIP: 98937L105
Event date: 2025-10-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SR One Capital Management, LLCReported CIK 0001853723
Shares: 5,037,854 · Class: 9.4%
- SR One Capital Fund II Aggregator, LP
Shares: 1,946,564 · Class: 3.6%
- SR One Capital Partners II, LP
Shares: 1,946,564 · Class: 3.6%
- AMZL, LP
Shares: 1,917,895 · Class: 3.6%
- SR One Capital SMA Partners, LP
Shares: 1,917,895 · Class: 3.6%
- SR One Capital Opportunities Fund I, LP
Shares: 1,173,395 · Class: 2.2%
- SR One Capital Opportunities Partners I, LP
Shares: 1,173,395 · Class: 2.2%
- Simeon George
Shares: 5,037,854 · Class: 9.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-239173
- Form type
- SCHEDULE 13D/A
- Filer
- SR ONE CAPITAL MANAGEMENT, LLC
- CIK
- CIK 1853723
- Filed
- Oct 14, 2025
- Reporting period
- Oct 09, 2025
- Description
- Schedule 13D beneficial ownership